Telix Partners with EDAP and Profound to Integrate PSMA-PET Imaging into HIFU and TULSA
Telix signed letters of intent with EDAP TMS and Profound Medical to integrate its PSMA-PET imaging agents Gozellix® and Illuccix® into robotic HIFU and TULSA image-guided ablative therapies for localized prostate cancer. The collaborations will focus on patient selection, treatment planning, monitoring and evidence generation to optimize personalized workflows.
1. Collaboration Agreements
Telix entered into letters of intent with EDAP TMS and Profound Medical to explore the integration of its PSMA-PET imaging agents, Gozellix® and Illuccix®, with minimally invasive ablative technologies for prostate cancer, including focal, subtotal and whole-gland approaches.
2. Integration with Robotic HIFU and TULSA
The agreements will evaluate the investigational use of PSMA-PET in conjunction with EDAP’s Focal One robotic high-intensity focused ultrasound system and Profound’s MRI-guided TULSA platform to guide energy delivery and optimize ablation accuracy.
3. Focus on Evidence Generation
Collaborative activities will emphasize non-promotional scientific and educational research, generating clinical evidence on patient selection, treatment planning and post-treatment monitoring to establish best practices for personalized workflows.
4. Potential Clinical Impact
By integrating molecular imaging into emerging therapy workflows, Telix aims to enhance clinical decision-making, preserve healthy tissue, minimize side effects such as incontinence and impotence, and accelerate adoption of precision prostate cancer treatments.